Edition:
United States

Evotec AG (EVTG.DE)

EVTG.DE on Xetra

18.70EUR
11:35am EDT
Change (% chg)

€-0.09 (-0.51%)
Prev Close
€18.80
Open
€18.75
Day's High
€18.88
Day's Low
€18.24
Volume
951,426
Avg. Vol
1,343,600
52-wk High
€19.36
52-wk Low
€4.70

Chart for

About

Evotec AG is a drug discovery and development company. The Company operates through two segments. The EVT Execute segment provides standalone drug discover services on a typical fee-for-service basis or integrated drug discovery collaborations on partners' target through a range of commercial structures, including research fees,... (more)

Overall

Beta: 0.62
Market Cap(Mil.): €2,765.15
Shares Outstanding(Mil.): 147.12
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 80.89 16.34
EPS (TTM): -- -- --
ROI: -- 3.08 14.66
ROE: -- 4.82 14.00

BRIEF-Evotec: EIB grants Evotec unsecured loan facility of up to EUR 75 mln

* DGAP-NEWS: EUROPEAN INVESTMENT BANK SUPPORTS EVOTEC'S INNOVATE STRATEGY WITH EUR 75 M LOAN

Sep 08 2017

German stocks - Factors to watch on September 7

FRANKFURT, Sept 7 The DAX top-30 index looked set to open 0.6 percent lower on Thursday, according to premarket data from brokerage Lang & Schwarz at 0649 GMT.

Sep 07 2017

BRIEF-Abivax and Evotec enter into strategic collaboration

* ABIVAX AND EVOTEC ENTER INTO STRATEGIC COLLABORATION TO DEVELOP NOVEL ANTIVIRAL AGENTS Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Sep 07 2017

BRIEF-Evotec completes acquisition of Aptuit

* Says completes acquisition of aptuit Source text for Eikon: Further company coverage:

Aug 16 2017

BRIEF-Evotec confirms outlook after H1 core profit jump

* Group revenues: 37% increase to eur 103.4 m (h1 2016: eur 75.5 m);

Aug 10 2017

German stocks - Factors to watch on August 7

FRANKFURT, Aug 7 The DAX top-30 index looked set to open 0.1 percent higher on Monday, according to premarket data from brokerage Lang & Schwarz at 0646 GMT.

Aug 07 2017

Evotec shares jump as Aptuit deal boosts contract research

FRANKFURT Shares in Evotec jumped on Monday after the German biotech firm struck a deal to acquire U.S. company Aptuit for $300 million to expand its outsourced drug discovery and development business.

Jul 31 2017

BRIEF-Germany's Evotec to acquire U.S.-based Aptuit for 256 mln euros

* Evotec to acquire Aptuit, expanding leadership in external innovation

Jul 30 2017

BRIEF-Evotec expands collaboration with Storm Therapeutics

* Says expands collaboration with Storm Therapeutics on its RNA epigenetics platform

Jul 27 2017

BRIEF-Evotec gets milestone payment from Bayer on endometriosis

* Says Evotec and Bayer advance endometriosis programme into phase I clinical development and extend alliance

Jul 24 2017

Earnings vs. Estimates